

BioCanRx Funded Core Facilities

BioCanRx has awarded funding to four Canadian academic facilities that offer translational services, including one organization that can support commercialization efforts. The Core Facilities program provides a baseline level of support for core facilities to enable their timely and cost-effective use by researchers of BioCanRx-funded projects.

The funded facilities are:

- **Immunotherapy Monoclonal Antibody Platform, Montreal Clinical Research Institute (IRCM)**
- **Molecular and Cellular Immunology Core (MCIC), BC Cancer**
- **Biotherapeutics Manufacturing Centre – Virus Manufacturing Facility, Ottawa Hospital Research Institute**
- **IRICoR, Commercialization Support, Université de Montréal**

The purpose of this document is to provide greater detail on the funded core facilities. We are happy to support further engagement with Core Facilities for potential collaboration. Please contact Megan Mahoney, Director of Scientific Affairs (memahoney@biocanrx.com).

IRICoR

Commercialization core for advanced therapeutics

What is IRICoR?

IRICoR (Institute for Research in Immunology and Cancer – Commercialization of Research) is a national leader in drug discovery and commercialization, with a primary focus on oncology, immunology and rare diseases. Established in 2008, IRICoR has developed extensive expertise in accelerating the translation of academic research into new therapies for the benefit of patients. By leveraging its integrated drug discovery pipeline and deep expertise in commercialization, IRICoR creates value around oncology and immunology assets originating from academic centers across Quebec and Canada. The organization progresses these assets rapidly and efficiently through the drug development continuum, generating partnership opportunities with industry and fostering the creation of spin-off companies. At the core of IRICoR's approach is its ability to bridge academic research and the biopharmaceutical sector.

What do they do?

IRICoR offers a suite of service offerings that support drug discovery.

Scientific Operations

By combining scientific expertise, project management, and operational oversight, IRICoR ensures the timely delivery of project milestones.

- Project planning and coordination
- Data and risk management
- Protocol development
- Competitive R&D landscape (clinical best practice) and intelligence gathering

Intellectual Property Support

IRICoR's integrated IP management plans are designed to protect project assets while maintaining flexibility for academic publication. This dual focus maximizes the commercial potential of each project.

- Tailored IP strategy
- Official project oversight
- Competitors insights and monitoring through advanced search tools

Business Development Support

IRICoR offers extensive business development support to drive market positioning and the commercial success of drug discovery projects. By identifying and securing strategic business opportunities—whether through industrial partnerships or start-up creation—IRICoR ensures projects are well-positioned to meet industry demands.

- Conference networking
 - Strategic partnering (licensing, collaboration, funding)
 - Negotiation and deal structuring
 - Market intelligence and competitive analysis
 - Alliance management
-

Why IRICoR?

Funding and Achievements (2008-Present):

- Government Funding: \$44M in subsidies for translational research.
- Additional Capital: \$170M from public and private sources (biopharma, grants, foundations).
- Biotech Spin-Outs: Successfully launched five companies
- Partnerships and Licensing: Over 12 agreements, totaling \$2B in upfront and milestone payments.

Intellectual Property Support

IRICoR's integrated IP management plans are designed to protect project assets while maintaining flexibility for academic publication. This dual focus maximizes the commercial potential of each project.

- Tailored IP strategy
- Official project oversight
- Competitors insights and monitoring through advanced search tools

Strategic Co-Investment Model:

- Leverages public and private funding to support projects.
- Collaborates with organizations like Ovarian Cancer Canada, Quebec Breast Cancer Foundation, FRQ-Oncopole, Genome Canada, BC Cancer.

Advancing Canadian Innovation in Cancer Therapeutics:

- Fosters innovation and collaborative research.
- Delivers transformative therapies to improve patient outcomes.

